874 Stock Overview
Researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$18.20 |
| 52 Week High | HK$24.20 |
| 52 Week Low | HK$16.62 |
| Beta | 0.58 |
| 1 Month Change | 0.55% |
| 3 Month Change | -14.55% |
| 1 Year Change | -17.83% |
| 3 Year Change | -20.52% |
| 5 Year Change | -31.06% |
| Change since IPO | -31.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 874 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 1.1% |
| 1Y | -17.8% | -20.9% | 17.6% |
Return vs Industry: 874 exceeded the Hong Kong Healthcare industry which returned -20.9% over the past year.
Return vs Market: 874 underperformed the Hong Kong Market which returned 17.6% over the past year.
Price Volatility
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 8.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in HK Market | 17.8% |
| 10% least volatile stocks in HK Market | 3.9% |
Stable Share Price: 874 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 874's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 28,760 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical equipment, and healthcare products; and research and development, production, and sale of beverages, food, healthcare products, and other products; and production and sale of pre-packaged food, dairy products, etc., as well as offers herbal tea, tablets, capsules, lozenges, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical services, health management, health maintenance, elderly care, etc.; and provides leasing and commercial, health, advertising, loading offloading, and warehouse services.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Fundamentals Summary
| 874 fundamental statistics | |
|---|---|
| Market cap | HK$46.50b |
| Earnings (TTM) | HK$3.64b |
| Revenue (TTM) | HK$81.27b |
8.1x
P/E Ratio0.4x
P/S RatioIs 874 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 874 income statement (TTM) | |
|---|---|
| Revenue | CN¥76.39b |
| Cost of Revenue | CN¥63.46b |
| Gross Profit | CN¥12.93b |
| Other Expenses | CN¥9.50b |
| Earnings | CN¥3.42b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 14, 2025
| Earnings per share (EPS) | 2.11 |
| Gross Margin | 16.92% |
| Net Profit Margin | 4.48% |
| Debt/Equity Ratio | 35.5% |
How did 874 perform over the long term?
See historical performance and comparisonDividends
4.7%
Current Dividend Yield55%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 18:25 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is covered by 28 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| null null | BOCI Research Ltd. |
| Sandra Sun | BofA Global Research |